COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) AFTER THE FAILURE OF A FIRST TNF INHIBITOR IN THE UNITED KINGDOM

被引：0
|
作者：
Pericleous, L. [1 ]
Lebmeier, M. [2 ]
机构：
[1] Bristol Myers Squibb Pharmaceut, Uxbridge, Middx, England
[2] Bristol Myers Squibb, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.417
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A307 / A308
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of rituximab (Mabthera) compared with abatacept (Orencia) for the treatment of moderate/severe rheumatoid arthritis (RA) in the united kingdom
    Lewis, G.
    Kielhorn, A.
    Diamantopoulos, A.
    VALUE IN HEALTH, 2007, 10 (06) : A249 - A250
  • [2] THE COST-EFFECTIVENESS OF ABATACEPT IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN THE UNITED KINGDOM
    Lebmeier, M.
    Pericleous, L.
    Drost, P.
    Dequen, P.
    Ouwens, M.
    Bergman, G.
    Baig, H.
    VALUE IN HEALTH, 2010, 13 (07) : A309 - A309
  • [3] A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY
    Brodszky, V
    Borgstrom, F.
    Arnetorp, S.
    Pentek, M.
    Gulacsi, L.
    VALUE IN HEALTH, 2008, 11 (06) : A549 - A550
  • [4] ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    VALUE IN HEALTH, 2013, 16 (03) : A223 - A224
  • [5] Cost effectiveness of the 3 TNF antagonists vs. Abatacept in the treatment of moderate to severe rheumatoid arthritis (RA)
    Davies, A.
    Cifaldi, M. A.
    Weisman, M. H.
    Segurado, O. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 278 - 278
  • [6] COST-EFFECTIVENESS OF ABATACEPT OR INFLIXIMAB IN RHEUMATOID ARTHRITIS IN COLOMBIA
    Alfonso-Cristancho, R.
    Aiello, E. C.
    Roa, C. N.
    VALUE IN HEALTH, 2011, 14 (03) : A127 - A127
  • [7] COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH TNF INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND
    Plisko, R.
    Krzystek, J.
    Rys, P.
    Russel-Szymczyk, M.
    Szkultecka-Debek, M.
    Szamotulska, K.
    VALUE IN HEALTH, 2008, 11 (06) : A544 - A544
  • [8] EFFECTIVENESS OF TNF INHIBITOR VERSUS ABATACEPT FOLLOWING TOCILIZUMAB FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Akiyama, M.
    Kaneko, Y.
    Kondo, H.
    Takeuchi, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 953 - 953
  • [9] COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN CHILE
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    VALUE IN HEALTH, 2013, 16 (03) : A223 - A223
  • [10] A COST-EFFECTIVENESS ANALYSIS OF ABATACEPT, TOCILIZUMAB, AND TNF-INHIBITOR COMPARED WITH RITUXIMAB AS A SECOND-LINE THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS
    Huoponen, S.
    Aaltonen, K. J.
    Joensuu, J. T.
    Rutanen, J.
    Relas, H.
    Taimen, K.
    Puolakka, K.
    Sokka, T.
    Nordstrom, D.
    Blom, M.
    VALUE IN HEALTH, 2016, 19 (07) : A538 - A538
12345